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Abstract
Background: Prostate cancer (PCa) is the most frequently diagnosed cancer in North American men. Androgen-deprivation
therapy (ADT) accentuates the infiltration of immune cells within the prostate. However, the immunosuppressive pathways
regulated by androgens in PCa are not well characterized. Arginase 2 (ARG2) expression by PCa cells leads to a reduced
activation of tumor-specific T cells. Our hypothesis was that androgens could regulate the expression of ARG2 by PCa cells.
Methodology/Principal Findings: In this report, we demonstrate that both ARG1 and ARG2 are expressed by hormone-
sensitive (HS) and hormone-refractory (HR) PCa cell lines, with the LNCaP cells having the highest arginase activity. In
prostate tissue samples, ARG2 was more expressed in normal and non-malignant prostatic tissues compared to tumor
tissues. Following androgen stimulation of LNCaP cells with 10 nM R1881, both ARG1 and ARG2 were overexpressed. The
regulation of arginase expression following androgen stimulation was dependent on the androgen receptor (AR), as a siRNA
treatment targeting the AR inhibited both ARG1 and ARG2 overexpression. This observation was correlated in vivo in
patients by immunohistochemistry. Patients treated by ADT prior to surgery had lower ARG2 expression in both non-
malignant and malignant tissues. Furthermore, ARG1 and ARG2 were enzymatically active and their decreased expression
by siRNA resulted in reduced overall arginase activity and L-arginine metabolism. The decreased ARG1 and ARG2 expression
also translated with diminished LNCaP cells cell growth and increased PBMC activation following exposure to LNCaP cells
conditioned media. Finally, we found that interleukin-8 (IL-8) was also upregulated following androgen stimulation and that
it directly increased the expression of ARG1 and ARG2 in the absence of androgens.
Conclusion/Significance: Our data provides the first detailed in vitro and in vivo account of an androgen-regulated
immunosuppressive pathway in human PCa through the expression of ARG1, ARG2 and IL-8.
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Introduction
Prostate cancer (PCa) is the most frequently diagnosed cancer
and third leading cause of cancer related deaths for North
American men [1]. The prostate’s organogenesis and carcinogen-
esis rely on the presence of androgens [2]. As such, the most
common treatment modality for men with an advanced stage or
recurrent PCa is androgen-deprivation therapy (ADT). ADT leads
to the apoptosis of hormone sensitive prostate epithelial cells [3].
Unfortunately, within one to five years following ADT initiation,
most patients develop hormone refractory PCa (HRPC), whose
treatment remains palliative [4]. New treatment modalities, such
as immunotherapy, attempt to tackle these later stages of PCa.
However, current immunotherapies against PCa have resulted in
limited success in the clinical settings. A detailed understanding of
the tumor immunological microenvironment in prostate cancer
patients should provide new insights on how to improve current
immune-based protocols.
Recent data demonstrate that various immunosuppressive
mechanisms are present within the prostate and may hamper
the anti-tumoral immune response in the context of an
immunotherapy (reviewed in [5]). Arginase 2 (ARG2) is expressed
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increases the activation of tumor-infiltrating lymphocytes (TILs)
[7]. While the immunosuppressive properties of arginases through
the metabolism of L-arginine are well documented (reviewed in
[8]), the regulation of human arginase expression, however, is
currently undefined.
Androgens are known to have immunosuppressive properties,
which is illustrated by the intra-prostatic inflammation following
ADT [9,10]. Gene expression analyses and murine studies suggest
that androgens regulate the expression of ARG2 and other
enzymes of the polyamine pathway [11,12,13]. Thus, considering
the fundamental roles of androgens in prostate carcinogenesis and
in the sculpting of the prostate’s microenvironment, we evaluated
whether androgens could regulate the expression of arginases by
PCa cells in vitro and in vivo.
In this study, we report that PCa cell lines express both
functionally active ARG1 and ARG2. Interestingly, hormone
sensitive (HS) and hormone refractory (HR) tissues expressed less
ARG2 than non-malignant tissues. In the HS LNCaP cell line,
androgen stimulation led to the increased expression of both
ARG1 and ARG2 in an androgen receptor (AR) dependant
manner. This androgen-regulated expression was also observed in
the primary tumor of ADT-treated patients who expressed less
ARG2 in both the non-malignant tissues adjacent to the tumor
and the tumor tissues compared to control patients. Finally, we
discovered that IL-8 was also regulated by androgens under the
control of the AR, and participated in the regulation of ARG1 and
ARG2 expression. Altogether, our data provides the first detailed
in vitro and in vivo account of an androgen-regulated immunosup-
pressive pathway in human PCa.
Results
ARG1 and ARG2 expression in PCa
We first evaluated arginases expression from PCa cell lines and
clinical samples. Our data demonstrate that PCa cell lines express
both ARG1 and ARG2. Gene expression analyses by qPCR
demonstrated that ARG1 mRNA was more abundant in the 22Rv1
cell line (Figure 1A), while ARG1 protein was slightly more
expressed by the two HR PCa cell lines (Du145 and PC3) than in
the LNCaP cells (Figure 1B, bottom panel). ARG1 protein
expression did not correlate with the gene expression analysis
suggesting a possible post-transcriptional regulation. As for ARG2
expression, the LNCaP cell line expressed the highest levels of
ARG2 mRNA (Figure 1A). Low ARG2 mRNA expression was
detected in the two HR cell lines DU145 and PC3 compared to
the two HS PCa cell lines. ARG2 protein abundance correlated
with the qPCR results with LNCaP cells expressing significantly
more ARG2 than the other three cell lines (Figure 1B, bottom
panel). Furthermore, LNCaP cells had the highest arginase activity
suggesting that ARG2 is the predominant enzyme with regards to
arginase activity of PCa cells (Figure 1B, top panel).
Expression of the ARG2 protein was evaluated in clinical
samples by immunohistochemistry on three different tissue micro-
arrays (TMAs) regrouping prostate samples from a cohort of 99
PCa patients and 50 normal prostate obtained from autopsies. We
did not evaluate ARG1 protein expression as, in our hands, anti-
ARG1 antibodies tested were not suitable for immunohistochem-
istry on archived formalin-fixed paraffin-embedded tissues. We
observed that ARG2 expression was restricted to the prostate
epithelium and absent from the stroma (Figure 1C). ARG2 was
statistically significantly less expressed in tumor tissues compared
to normal (p,0.001, Mann-U), to non-malignant normal adjacent
(p,0.01, Mann-U) and to prostate intraepithelial neoplasia (PIN)
tissues (p,0.001, Mann-U) (Figure 1D). HR tissues also expressed
less ARG2, although only significantly different from PIN tissues
(p=0.033, Mann-U). There was no correlation between ARG2
expression within the normal adjacent and tumor tissues (Table
S1). Finally, we evaluated if the ARG2 expression correlated with
clinico-pathological parameters such as Gleason Score, pre-
operative prostate specific antigen (PSA) levels and biochemical
recurrence. Our results show that ARG2 expression within the
normal adjacent tissue inversely correlated with vesicle seminal
invasion (Table S1). Altogether, these in vitro and in vivo data
demonstrate the differential expression of ARG1 and ARG2
between various stages of PCa progression, independently of the
HR status.
Androgen-regulated expression of ARG1 and ARG2
The differential expression of ARG1 and ARG2 between the
HS and HR PCa cell lines led us to investigate the regulatory roles
of androgens in arginase expression. To do so, we evaluated
arginases gene and protein expression following androgen
stimulation. ARG1 mRNA expression was not statistically
significantly upregulated in either LNCaP or 22RV1 cell lines
following R1881 stimulation (Figure 2A). However, in LNCaP
cells, ARG2 mRNA expression was increased at 48 hours
(p=0.002, Mann-U) and at 72 hours (p=0.016, Mann-U)
following the R1881 stimulation (Left panel, Figure 2B). The
overexpression of ARG2 in 22RV1 was not statistically significant
(p=0.248, Mann-U) (Right panel, Figure 2B). In fact, ARG2
expression correlated with the higher androgen sensitivity of
LNCaP cells compared to 22RV1 (Figure S1A). As such, LNCaP
cells were used for further experiments. Corroborating the PCR
data, Western blots from LNCaP cells demonstrated that the
R1881 stimulation increased ARG2 protein expression
(Figure 2C). Interestingly, although no significant changes were
observed in ARG1 mRNA expression in LNCaP cells treated with
R1881, ARG1 protein expression was significantly increased. We
did not observe any increases in ARG1 or ARG2 protein
expression in DU145 and PC3 stimulated with 10 nM of R1881
(Figure S1B).
The AR is implicated in ARG1 and ARG2 expression
As our results suggest that androgens regulate arginase
expression, we evaluated the contribution of the AR. We inhibited
AR activity with the non-steroidal anti-androgen bicalutamide
(Casodex) (Figure 2D). We noted a decreased expression of ARG1
with the highest concentration (40 mM) of bicalutamide following
R1881 stimulation. The androgen induction of ARG2 was not
blocked, even at the highest concentration of bicalutamide. As
previously documented [14], we observed that bicalutamide had
AR-agonist activity in LNCaP cells cultured in the absence of
androgens. There was an R1881-independant induction of PSA
and ARG2 expression in LNCaP cells stimulated with 20 mM and
40 mM of bicalutamide in the absence of androgens. In this same
condition, bicalutamide caused a decrease in ARG1 expression.
These results suggest that ARG1 expression may be more sensitive
to AR inhibition than ARG2, whose expression was induced by
the agnostic effect of the AR inhibitor.
We decided to further inhibit the AR by blocking the AR
expression in LNCaP cells using siRNA. The presence of siRNA
against the AR resulted in a significant inhibition of AR expression
and in a reduced PSA expression following R1881 stimulation
(Figure 2E). Both the ARG1 and ARG2 induction following
R1881 stimulation were inhibited by the siRNA treatment, which
translated in the absence of an upregulation in arginase activity
(Figure 2F). These results suggest that the AR regulates the
Androgens, ARG1, ARG2 and IL-8
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have a different sensitivity to AR inhibition.
Diminished ARG2 expression in PCa patients following
ADT
Based on our in vitro data, we hypothesized that androgens
might modulate ARG2 protein expression in PCa patients as well.
We observed that, compared to control cancer patients (surgery
only), ADT-treated patients (ADT prior to surgery) had signifi-
cantly lower ARG2 expression in both the non-malignant tissues
adjacent to the tumor (46.4 vs 23.5 relative units; p,0.001, Mann-
U) and the tumor tissues (41.7 vs 31.5 relative units; p,0.01,
Mann-U) (Figure 3A). We also observed that androgen deprivation
in vitro could decrease ARG2, but not ARG1 protein expression, in
LNCaP and 22RV1 cells cultured for seven days in the absence of
androgens (Figure 3B). Taken together, these results suggest that
androgens regulate the expression of ARG2 in vivo in PCa patients
as ADT reduces ARG2 expression.
ARG1 and ARG2 are metabolically active
To evaluate whether ARG1 and ARG2 expressed by LNCaP
cells were metabolically active, we inhibited the expression of
either ARG1 or ARG2 by siRNA. Compared to a siCTRL, both
siRNA significantly inhibited ARG1 or ARG2 expression
Figure 1. In vitro and in vivo expression of ARG1 and ARG2 in PCa. PCa cell lines (LNCaP, 22Rv1, DU145 and PC3) were maintained in RPMI
supplemented with 10% FBS. A) Gene expression of ARG1 (left panel) and ARG2 (right panel). Mean relative expression (n=3) with standard error of
the mean (error bars). B) Top panel: Arginase activity of PCa cell lines quantified in mU/mg of proteins. Bottom panel: Western blot of ARG1 and
ARG2. Ran served as loading control. C) Representative image of immunohistochemistry staining of ARG2 expression in prostatic tissue. Note that the
expression of ARG2 was confined to the epithelial cells with no stromal staining. D) Quantification of ARG2 expression by immunohistochemistry in
prostate specimens. *Statistically significant difference in ARG2 expression between PIN and HR tissues (p=0.033, Mann-U). **Statistically significant
difference in ARG2 expression between tumor tissues and normal tissues (p,0.001, Mann-U), non-malignant tissues adjacent to tumor (p,0.01,
Mann-U) and PIN tissues (p,0.001, Mann-U).
doi:10.1371/journal.pone.0012107.g001
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PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12107Figure 2. Androgen-regulated expression of ARG1 and ARG2. A-B) LNCaP cells (left panels) and 22RV1 (right panels) were stimulated over a
period of 72 hours with 10 nM R1881 following a 72 hour incubation period in charcoal-stripped media and the gene expression of A) ARG1 and B)
ARG2 analyzed by qPCR. Control (light gray bars) and R1881-stimulated (black bars). *Statistically significant difference (p,0.05, Mann-U). Mean
relative expression (n=4) with standard error (error bars). C) Increased protein expression of both ARG1 and ARG2 following R1881 stimulation by
Western blot. LNCaP cells were stimulated with 10 nM R1881 as previously described. PSA served as positive control. Representative experiment,
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diminished arginase enzymatic activity (Figure 4B). By HPLC, we
then determined the impact of the inhibition of ARG1 and ARG2
expression on the metabolism of L-arginine by LNCaP cells. The
absence of either ARG1 or ARG2 led to higher concentrations of
L-arginine in the conditioned media suggesting a lower metabolism
of L-arginine by LNCaP cells (Figure 4C). Moreover, we noted
that R1881 stimulation led to a decreased concentration of
extracellular L-arginine, which corroborates our results demon-
strating an increased arginase expression following androgen
stimulation. We evaluated the expression of nitric oxide synthase
(NOS), also known to metabolize L-arginine. However, we did not
observe the expression of iNOS or nNOS (protein) as well as no
production of NO (function) in our model (data not shown).
As arginases are implicated in the polyamine synthesis pathway
necessary for cellular proliferation, we evaluated the impact of
ARG1 and ARG2 on cell growth. We observed that inhibition of
either ARG1 or ARG2 expression resulted in a lower proliferation
of LNCaP cells maintained in complete media (p=0.02 and
p=0.01, respectively for siARG1 and siARG2) (Figure 4D).
Furthermore, in order to study whether ARG1 and ARG2
expression by LNCaP cells affected their immunosuppressive
potential, PBMCs from healthy donors were activated in the
presence of conditioned media from LNCaP+siCTRL or
LNCaP+siARG1 or LNCaP+siARG2. The inhibition of either
ARG1 or ARG2 translated into increased PBMC proliferation as
quantified by BrdU incorporation (Figure 4E, left panel). This
increased proliferation was associated with an elevated IFN-c
secretion by PBMCs as measured by ELISA (Figure 4E, right
panel). No significant variations in the secretion of IL-2 or IL-10
were observed (data not shown). Finally, we evaluated whether the
ARG2 expression correlated with the immune cell infiltrate of the
primary tumor that we recently published [10]. We noted that
ARG2 expression did inversely correlate with the infiltration of T
lymphocytes and macrophages within the prostate (Table S2).
Collectively, these results suggest that ARG1 and ARG2 expressed
by LNCaP cells are enzymatically active and participate in
important physiological processes such as cellular proliferation and
tumor-derived immunosuppression.
IL-8 induction of ARG1 and ARG2 expression
As arginases are well-documented to participate in the sculpting
of the tumor immunological microenvironment [15] and that
cytokines are known to induce arginase expression in murine
models [16], we assessed whether cytokines could also regulate
arginase expression in human PCa. The cytokine expression
profile of LNCaP cells stimulated with 10 nM of R1881 was
qualitatively evaluated using a Proteome Profiler cytokine array
(R&D Systems) (Figure 5A). The proteomic data illustrated that
the R1881-stimulated LNCaP cells had increased expression of IL-
8 and Serpin E1 (Figure S2A). We further investigated the role of
IL-8 in arginase expression as IL-8 has been recently linked to the
expression of androgen-regulated genes in PCa [17]. We thus
quantified the elevated expression of IL-8 in LNCaP cells
following R1881 expression (Figure 5B). This IL-8 induction was
dependent on the AR as the inhibition of AR expression by siRNA
prevented IL-8 secretion following androgen stimulation
(Figure 5C). We then evaluated whether inhibition of IL-8 could
diminish ARG1 and ARG2 expression following R1881 stimula-
tion. Using a siRNA against IL-8, we could significantly diminish
(n=6). D) Inhibition of AR activity with bicalutamide (Casodex). LNCaP cells were stimulated with R1881 for 72 hrs as previously described in the
presence of increasing doses of bicalutamide (0, 10, 20 and 40 mM). ARG1 and ARG2 expression levels were evaluated by Western blot. Representative
experiment is shown, (n=3). Note the agonist effect of bicalutamide in the absence of R1881 illustrated by an increased PSA and ARG2 expression. E)
Inhibition of AR expression by siRNA. LNCaP cells were transfected as previously described. AR, ARG1 and ARG2 expression levels were evaluated by
Western blot. Representative experiment is shown, (n=4). F) Arginase activity was quantified in mU/mg of proteins. LNCaP cells were transfected
with siCTRL (light gray bars) or siAR (black bars) and then stimulated with R1881 for 72 hrs as previously described. Representative experiment,
(n=3).
doi:10.1371/journal.pone.0012107.g002
Figure 3. Reduced ARG2 expression following ADT. A) Analysis of androgen-regulated ARG2 expression in PCa patients by
immunohistochemistry. Control patients (light gray bars, n=40) and ADT-treated patients (black bars, n=35). B) Decreased ARG2 protein
expression in the absence of androgens in vitro determined by Western blot. Ran served as loading control. PCa cell lines (LNCaP, 22Rv1, DU145 and
PC3) were maintained in RPMI 10% FBS or in RPMI supplemented with 10% charcoal stripped FBS for 7 days (n=3). Note that ARG1 expression did
not vary but that ARG2 was reduced in LNCaP and 22Rv1 cells in the absence of androgen.
doi:10.1371/journal.pone.0012107.g003
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12107Figure 4. ARG1 and ARG2 are metabolically active. LNCaP cells were transfected with either a siCTRL or a cocktail of three siRNA against the
ARG1 or ARG2. Post-transfection (24 hours), cells were plated in charcoal-stripped serum supplemented media for 72 hours and then stimulated for
72 hours with 10 nM R1881. A) siRNA inhibition of ARG1 and ARG2 expression was evaluated by Western Blot. Representative experiment is shown,
(n=4). B) Decreased arginase activity following transfection with siARG1 or siARG2 in LNCaP cells. The corresponding Western blot is shown in the
Androgens, ARG1, ARG2 and IL-8
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associated with a reduction of ARG1 and ARG2 24 hrs following
R1881 stimulation (Figure 5E). The treatment of LNCaP cells with
siIL-8 also translated to a decrease in arginase activity (Figure
S2B). Finally, we stimulated androgen-deprived LNCaP cells with
increasing concentration of exogenous IL-8 for 72 hrs and
monitored the expression of ARG1 and ARG2. By Western blot
analysis, we observed that both 50 ng/ml and 100 ng/ml of IL-8
induced the expression of ARG1 and ARG2 when compared to
control LNCaP cells (Figure 5F). The decrease in ARG1 and
ARG2 protein expression with 250 ng/ml of IL-8 correlated with
IL-8 induced cellular toxicity. We also observed an induction of
ARG2, but not ARG1, gene expression after a 24 hr stimulation
(Figure S2C). Finally, as it was previously reported that phenol red
could activate the AR [18], we also stimulated LNCaP cells with
IL-8 in phenol red-free RPMI media. These control experiments
demonstrated that IL-8-dependent induction of ARG1 and ARG2
could occur in the absence of phenol red (Figure S2D). Taken
together, the data clearly shows that androgens regulate the
expression of IL-8, which on its own can induce the expression of
both ARG1 and ARG2.
Discussion
A more thorough understanding of the prostate immunological
microenvironment mechanisms may improve the clinical efficacy
of current immunotherapies against PCa. We and others have
shown that ADT leads to drastic changes in the prostate
immunological microenvironment [9,10]. The arginase pathway
participates in the development of an immunosuppressive state
within the primary tumor of PCa patients [7]. However, the
regulation of arginase expression by PCa cells remains undefined.
In this report, we observed that androgens induced the
expression of both ARG1 and ARG2 in HS PCa cell lines. The
AR was implicated in this regulation as both bicalutamide and
siAR transfection prevented ARG1 and ARG2 overexpression
following R1881 stimulation. Reciprocally, androgen deprivation
and ADT reduced ARG2 expression in vitro and in the primary
tumor of PCa patients, respectively. LNCaP cells expressed
enzymatically functional ARG1 and ARG2 which, once their
protein expression was inhibited, caused a decrease in cellular
proliferation and in their immunosuppressive potential. Finally, we
showed that IL-8 was also regulated by R1881 and could stimulate
the expression of ARG1 and ARG2 independently of androgen.
Altogether, our results provide the first mechanistic evidence of an
androgen-driven immunosuppressive pathway in PCa through the
expression of ARG1, ARG2 and IL-8 by PCa cells.
We demonstrate that PCa cells express both ARG1 and ARG2.
ARG2 was predominantly expressed by HS PCa cell lines and by
non-malignant prostate tissues. These results corroborate pub-
lished data describing a lower ARG2 expression in androgen-
insensitive PCa cell lines (DU145 and PC3) and in the tumor and
HR tissues of PCa patients [6,19]. However, to our knowledge, we
are the first group to study the expression of ARG1 by PCa cells
and define mechanistic consequences leading to its androgen-
regulated induction. Similar to ARG2, inhibition of ARG1
expression led to decreased tumor cell proliferation, reduced L-
arginine metabolism and reduction of their immunosuppressive
potential. Based on the protein expression (Figure 1B, bottom
panel) and on the arginase activity of PCa cells (Figure 1B, top
panel), our data suggest that ARG2 may nonetheless have a more
prominent role than ARG1 in the arginase activity potential of
PCa cells [20].
Furthermore, our data showed that ARG1 and ARG2 were
differentially regulated by androgens. Contrary to ARG2 gene and
protein expression, we clearly demonstrated that the gene and
protein expression of ARG1 did not correlate. This suggests that
androgens may influence a post-transcriptional regulation of
ARG1 as it was previously reported in xenopus [21] and in yeast
models [22]. Since ARG2 expression is localized to mitochondria,
we evaluated whether cellular proliferation independent of
androgens could induce ARG2 expression in LNCaP cells. In a
proliferation assay with EGF instead of R1881, no ARG2
induction was observed (data not shown). Collectively, our results
reveal that, although both induced by R1881, the signaling
pathways leading to ARG1 and ARG2 expression differ for the
two enzymes and need to be further examined.
The implication of an androgen-regulated expression of ARG1
and ARG2 in prostate carcinogenesis requires further investiga-
tion. Arginase expression and polyamine synthesis are elevated in
PCa [23,24] and associated with tumor grade [25]. A high
arginase activity correlates with increased proliferation of breast
cancer [26], colon cancer [27] and kidney cell lines [28]. However,
we observed that tumor or HR tissues express less ARG2 than
non-malignant tissues. It is possible that tumor cells do not acquire
the expression of these enzymes as a mean to further exploit their
immunosuppressive potential, an aspect associated with tumor
progression. In fact, since the prostate is the organ with the highest
polyamine production, arginase expression by prostate cells may
precede the development of cancer, as polyamine production is
essential for the proliferation of prostate cells. Thus, the
immunosuppressive advantage gained by prostate cells may be
secondary to the proliferative role played by the arginases. From
our data and that of others, we hypothesize that arginase may be
implicated in the earlier hormone-sensitive stages of prostate
carcinogenesis by promoting cancer cell proliferation and the
development of an androgen-regulated immunosuppressive envi-
ronment.
Finally, we observed that IL-8 was upregulated following
androgen stimulation and could induce the expression of ARG1
and ARG2. IL-8 mediates its effects through the activation of two
high-affinity G-protein coupled receptors, CXCR1 and CXCR2
[29], both of which are expressed by LNCaP cells [30,31]. It is
important to note that expression of ARG1 and ARG2 following
bottom panel. Representative experiment is shown, (n=3). C) Decreased metabolism of L-arginine in the absence of arginase expression. Conditioned
media of LNCaP cells transfected with siCTRL, siARG1 or siARG2 were analyzed by HPLC for L-arginine concentration. The conditioned media analyzed
by HPLC were from the LNCaP cells presented in Figure 4A. *Statistically significant difference (p,0.05, Mann-U). D) Decreased proliferation of LNCaP
cells in the absence of arginase expression. LNCaP cells were transfected as previously described. Proliferation was measured by cell count 96 hours
post-transfection. *Statistically significant difference (p,0.05, Mann-U), (n=3). E) Inhibition of ARG2 expression causes increased PBMC proliferation
and activation. PBMCs from normal donors were activated with anti-CD3 (OKT3, 1 mg/ml) with or without IL-2 in the presence of fresh media or
conditioned media of LNCaP cells transfected with either control, siCTRL, siARG1 or siARG2 as previously described. Control PBMCs were incubated
with IgG isotype control (1 mg/ml) and with PBS instead of IL-2. Left panel: PBMC proliferation was quantified by BrdU incorporation following
120 hours of OKT3 and IL-2 stimulation. Mean absorbance (n=4) is shown with standard error (error bars). Right panel: PBMC secretion of IFN-c
quantified by ELISA. Same experiment as previously described, but the PBMCs were activated for 24 hours without IL-2. Representative expression is
shown (n=4) with standard error of the mean (error bars).
doi:10.1371/journal.pone.0012107.g004
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PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12107Figure 5. Androgens induced Interleukin-8, which in turn promotes ARG1 and ARG2 expression. Evaluation of the cytokine expression
profile of LNCaP cells following R1881 stimulation. A) Conditioned media of LNCaP cells stimulated as previously described were analyzed with a
Proteome Profiler
TM (R&D Systems). B) Conditioned media of LNCaP cells stimulated over time with either ethanol control (light gray bars) and R1881
(black bars) were analyzed for the production of IL-8 by ELISA. The representative experiment showed was performed with the same conditioned
media used for the Proteome Profiler analysis in 5a, (n=3). C) Quantification of IL-8 secretion by LNCaP cells transfected with siAR and stimulated
with R1881 as previously described. Representative experiment is shown, (n=3). D) Quantification of IL-8 secretion by LNCaP cells transfected with
siIL-8 and stimulated with R1881 as previously described. Representative experiment is shown, (n=3). For 5b and 5c, there was no IL-8 secretion
detected in the absence of R1881 stimulation. E) Expression of ARG1 and ARG2 in LNCaP cells following transfection of siIL-8 and R1881 stimulation
for 24 hours. Representative experiment is shown, (n=3). F) LNCaP cells were plated in charcoal-stripped serum supplemented media for 72 hours
and for 24 hours in serum-free RPMI. Cells were then stimulated for 72 hours with 10 nM R1881 or with 50, 100 or 250 ng/ml of IL-8 in serum-free
RPMI. ARG1 and ARG2 expression levels were detected by Western blot. Representative experiment, (n=3). Note the induction of both ARG1 and
ARG2 at 50 and 100 ng/ml of IL-8 concentration in the absence of R1881.
doi:10.1371/journal.pone.0012107.g005
Androgens, ARG1, ARG2 and IL-8
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12107IL-8 stimulation was not as substantial as with R1881 stimulation
suggesting that other androgen-regulated pathways could be
involved. Altogether, this is the first indication that the expression
of IL-8 is regulated by androgens and that arginases can be
regulated by cytokine in human cancer cells.
Conclusion
Our data demonstrate that androgens regulate the expression of
both ARG1 and ARG2 in HS PCa cell lines and in PCa patients
in an AR-dependent manner. ARG1 and ARG2 are enzymatically
active and their inhibition results in reduced L-arginine metabo-
lism, cell growth and immunosuppressive potential. We found that
IL-8 secreted by LNCaP cells was also regulated by androgens and
could on its own promote the expression of ARG1 and ARG2.
Collectively, the results presented in this report suggest that
androgens actively participate in the development of an immuno-
suppressive microenvironment within the prostate through the
expression of ARG1 and ARG2. A better understanding of the
expression of immunosuppressive pathways at specific stages of
PCa progression may eventually provide new insights for
improving current immunotherapeutic strategies.
Materials and Methods
Cell Culture
LNCaP, 22Rv1, DU145 and PC3 cell lines were obtained from
ATCC (MD, USA). All cell lines were maintained as previously
described by our group [32]. For R1881 stimulation, cells were
plated at 600,000 cells per 60 mm petri dish and incubated for an
initial 72 hours in 10% (v/v) charcoal-stripped fetal calf serum
(FCS)-supplemented RPMI 1640, which eliminates all steroid
hormones from the serum. Afterwards, the cells were washed with
PBS and cultured in fresh 10% charcoal-stripped FCS-supple-
mented RPMI 1640, with either 10 nM R1881 or ethanol
(control) [32]. As control experiments, phenol red-free RPMI
was purchased from Wisent (St-Bruno, QC) and was supplement-
ed with 20 mM of L-glutamine (Wisent). Conditioned media,
protein and RNA were extracted at 0, 24, 48 or 72 hours following
the R1881 stimulation. For IL-8 stimulation, LNCaP cells were
plated in charcoal-stripped serum supplemented media for
72 hours followed by 24 hours in serum-free RPMI. Cells were
then stimulated for 72 hours with either 10 nM R1881 or with
100 ng/ml IL-8 (PeproTech, Rocky Hill, NJ) in serum-free RPMI.
siRNA targeting the AR, ARG1, ARG2 and IL-8 as well as the
RISC-free siGLO fluorescent siRNA control were purchased from
Dharmacon (Chicago, IL). When LNCaP cells reached 80%
confluence in a 100 mm petri dish they were transfected as
recommended by the manufacturer using the Dharmafect 2
transfection reagent. Cells were incubated for 24 hrs after which
they were seeded as described for the R1881 stimulation.
siRNA sequences
The siRNAs were all purchased from Dharmacon and consisted
of pools of four sequences.
AR siRNA sequences (catalog # M-0034-00-00): GGAACUC-
GAUCGUAUCAUUUU; CAAGGGAGGUUACACCAAAUU;
UCAAGGAACUCGAUCGUAUUU; GAAAUGAUUGCACU-
AUUGAUU. ARG1 siRNA sequences (catalog # L-009922-00):
GGACUGGACCCAUCUUUCA; GGGCGGAGACCACAGU-
UUG; GGGCUACUCUCAGGAUUAG; GAAGUAACUC-
GAACAGUGA. ARG2 siRNA sequences (catalog # M-091965-
00): GAUCAAACCUUGUAUCUCUUU; UCAGAGAACUA-
CAGGAUAAUU; GAACUAUGAUAUCCAGUAUUU; GGA-
CUAACCUAUCGAGAAGUU. IL-8 siRNA sequences (catalog
# L-004756-00): GCAUAAAGACAUACUCCAA; CCACCA-
CACUGCGCCAACA; GCCAAGGAGUGCUAAAGAA; UG-
AAGAGGGCUGAGAAUUC.
Antibodies
The following antibodies were purchased from Santa Cruz
(Santa Cruz, CA): anti-ARG1 (BC9, sc-47715), anti-ARG2 (L-20,
sc18357), anti-PSA (C-19, sc-7638), anti-RAN (C-20, sc-1146).
The anti-AR (Ab-1) was purchased from LabVision/NeoMarkers
(Fermont, CA) and the anti-GAPDH (ab9485) from AbCam
(Cambridge, MA).
Gene and Protein Expression
Quantitative real-time PCR (qPCR) analyses were performed as
previously described by our group [33]. RAN served as the
housekeeping gene as we found that its expression was not sensitive
to R1881 stimulation. Relative mRNA of candidate gene/RAN
ratios were calculated using the method described by Pfaffl et al.
[34]. Fold change was calculated relative to the mock treated
control. Western blotting of proteins extracted in non-denaturing
buffer was performed as previously described by our group [35].
Arginase Activity
Arginase activity was quantified as previously described [36].
Briefly, a solution of 10 mM MnCl2/50 mM Tris/HCl at pH 7.5
was added to whole cell extracts. Following an incubation at 55uC
for 60 mins, 25 ml of 0.5 M arginine pH 9.7 was added to the
samples and further incubated for 60 mins at 37uC. The arginine
hydrolysis reaction was stopped by adding H2SO4/H3PO4/H2O
at a ratio of (1:3:7, v/v/v). The samples were then boiled at 100uC
for 15 mins following the addition of 9% ISPF and read at
540 nm. Using a standard curve, arginase activity was reported as
mUnits/mg of protein.
Immunohistochemistry on PCa TMAs
Four different tissue microarrays (TMAs) were used in this
study. The first TMA contained 50 normal prostate specimens
obtained from 39 autopsied patients without PCa. The second
TMA contained non-malignant tissue adjacent to tumor
(n=55), prostate intra-epithelial neoplasic (PIN) tissue (n=32)
and HS tumor tissue (n=63) from 63 patients who had
undergone radical prostatectomy [37]. The third TMA
contained HR tumor tissues obtained by trans-urethral
resection of the prostate (TURP) from 36 patients collected
subsequent to hormone therapy failure [38,39]. Finally, the
fourth TMA contained prostate specimens obtained from 35
patients who were treated by ADT prior to radical prostatec-
tomy (ADT group) and 40 Gleason-matched control patients
who were only treated by radical prostatectomy, as previously
described [10]. For each patient, a total of four tumor cores and
two normal adjacent cores were spotted on duplicate TMAs.
Cell pellets of each PCa cell line (RWPE, LNCaP, 22Rv1,
DU145 and PC3) were spotted on each array and served as
internal staining controls. Ethics approval for this study was
obtained from the local ethics review committee, the Comite ´
d’e ´ t h i q u ed uC e n t r ed er e c h e r c h ed uC e n t r eH o s p i t a l i e rd e
l’Universite ´d eM o n t r e ´al (CRCHUM). Furthermore, informed
written consent was obtained from all participants involved in
this study, including from the families of the autopsied patients.
Immunohistochemical staining was done as previously de-
scribed by our group [39,40,41]. Briefly, the 90 min primary
antibody incubation was followed by 30 min incubation with an
anti-mouse HRP-coupled secondary antibody (sc-2005, Santa
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(DAB) (Dako Cytomation, Mississauga, On, Canada) and the
nuclei were counterstained with haematoxylin. High-resolution
digital images of each TMA were generated using a whole-slide
scanner (SanScope XT automated high-throughput scanning
system) from Aperio (Vista, CA). Two independent observers
evaluated the intensity (0, 1+,2 +,3 +) and the percentage of
positively stained cells. For each core a value corresponding to the
intensity multiplied by the percentage of stained cells was
calculated and reported for statistical analysis.
Quantification of L-Arginine concentration by HPLC
Perchloric acid (150 ml) was added to conditioned media
(150 ml), which was then vortexed and shook for 10 min. The
samples were then centrifuged (13,000 rpm) for 20 min and 240 ml
of supernatant were transferred into an amber eppendorff tube.
This solution containing the L-arginine was thus essentially cleared
of cellular proteins [42]. The supernatant was then neutralized
with 60 ml of 3 M NaOH and buffered to pH 9.0 using 180 mlo f
borate buffer. To this solution, 10 ml of 0.1 M NaCN and
Naphthalene-2,3-dicarboxaldehyde (NDA) were added and shak-
en for 20 min before injection into the HPLC. All samples were
run on a Varian Pursuit C18 column 25064.6 mm with the
following three solvents: Solvent A: 100 mM triethylammonium
acetate (TEAA) buffered to pH 7.0 with 5% acetonitrile (ACN) in
milli-Q water; Solvent B: 60% ACN in Solvent A; Solvent C:
100% ACN. A series of L-arginine standards were made ranging
from 0 to 2.58610
24 g/ml. Each standard was done in triplicate
and was functionalized with NDA to determine the retention time
of L-arginine and the area under the peak corresponding to L-
arginine at specific concentrations. Samples were monitored at
260 nM and 420 nM to identify which samples had been
functionalized with the NDA. Peaks that appear at 420 nM
correspond to substances that have a primary amine available to
react.
Lymphocyte activation
PBMCs from healthy donors were isolated from whole blood by
Ficoll gradient using lymphocyte-separating medium (Wisent, St-
Bruno, Qc, Canada). PBMCs (150,000) were incubated in a 96-
well flat-bottomed plate with 1 mg/ml of plate-bound anti-CD3
(OKT3, eBioscience, San Diego, CA) or an isotype control.
Supernatants were harvested for cytokine quantification by
enzyme-linked immunosorbent assay (ELISA). For proliferation
assays, bromodeoxyuridine (BrDU) was added in the last 12 hrs
according to the manufacturer’s instruction. Informed written
consent was obtained from all healthy donors involved in this
study.
ELISA
The ELISA kit for IL-8 was purchased from R&D Systems
(Minneapolis, MN) and the cell proliferation BrDU ELISA kit
from Roche (Mississauga, ON, Canada). ELISAs were done
according to the manufacturer’s instruction. The IFN-c ELISA
was completed as previously described [43].
Proteome Profiler Analysis
T h ep r o t e o m ep r o f i l e rHuman Cytokine Array Panel A Array Kit
(R&D Systems) was used according to the manufacturer’s
instructions. Briefly, the membranes were incubated with
conditioned media from LNCaP cells stimulated with R1881,
as previously described, in the presence of the supplied
antibody cocktail. Following washes and incubation with a
Streptavidin-HRP buffer, positive signal was revealed using
ECL reagent.
Statistics
Statistical analysis was performed using SPSS software 11.0
(SPSS Inc., Chicago, Il). The non-parametric Mann-Whitney U
test was used to show statistically significant differences.
Supporting Information
Table S1 Correlations between ARG2 expression and clinico-
pathological markers.
Found at: doi:10.1371/journal.pone.0012107.s001 (0.05 MB
XLS)
Table S2 Correlations between ARG2 expression and immune
cell infiltration.
Found at: doi:10.1371/journal.pone.0012107.s002 (0.05 MB
XLS)
Figure S1 Androgen stimulation of PCa cells. A) LNCaP cells
(left panels) and 22RV1 (right panels) were stimulated over a
period of 72 hours with 10 nM R1881 following a 72 hour
incubation period in charcoal-stripped media and the gene
expression of Prostate-Specific Antigen (PSA), a positive control
for R1881 stimulation, was analyzed by qPCR. Note that the
ARG2 gene expression presented in Figure 1A correlated with the
higher androgen sensibility of LNCaP cells compared to 22RV1 as
exemplified by the mRNA expression of PSA. B) Expression of
ARG1 and ARG2 determined by Western blot in LNCaP, Du145
and PC3 cells stimulated with R1881 for 72 hours as previously
described. Note the absence of ARG1 and ARG2 in the two HR
PCa cell lines, DU145 and PC3.
Found at: doi:10.1371/journal.pone.0012107.s003 (0.72 MB TIF)
Figure S2 ARG1 and ARG2 induction following IL-8 stimula-
tion. A) Positive signals from the Proteome Profiler
TM were
quantified by densitometry using Quantity One software (Bio-
Rad). Ethanol control (gray bars) and R1881 (black bars).
B) Arginase activity of LNCaP cells transfected with siCTRL,
siAR or siIL-8 and then stimulated with R1881 was quantified in
mU/mg of proteins. Same representative experiment as presented
in Figure 2F, (n=3). C) Increased ARG2 gene expression at
24 hours following IL-8 stimulation. LNCaP were stimulated with
IL-8 as previously described. Ran served as the loading control. D)
LNCaP cells were plated in charcoal-stripped serum supplemented
phenol red-free RPMI media for 72 hours and subsequently for
24 hours in serum-free, phenol red-free RPMI. Cells were then
stimulated for 72 hours with 10 nM R1881 or with 5 nM of IL-8
in serum-free, phenol red-free RPMI. ARG1 and ARG2
expression levels were detected by Western blot. Representative
experiment is shown, (n=2).
Found at: doi:10.1371/journal.pone.0012107.s004 (1.43 MB TIF)
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